Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID-MAGIC: Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children
NCT06574789Phase 2Recruiting
- Sponsor
- Murdoch Children's Research Institute
- Start
- Oct 2024
- Primary completion
- Jun 2028
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of ganciclovir in cytomegalovirus infection, sponsored by Murdoch Children's Research Institute. Started Oct 2024; status: recruiting.
02
Drugs
ganciclovir
03
Conditions
cytomegalovirus infection
Beyond the preview
Go deeper on NCT06574789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574789.